TW
EN

About UBIP
Technology Platform
RD & Products
Quality
CMO/CDMO Services
- Tailored Solutions
- Facility & Capacity
News
- Press Release
- Media Coverage
Contact us

Search

News

Press Release
- UBI Pharma’s UB-851, a Biosimilar Short-Acting Recombinant Human Erythropoietin, Demonstrates Strong Clinical Biosimilarity and Earns Publication in an International Medical Journal
- Our company's new compound drug NDF01 for the treatment of HIV infection has been approved by the Ministry of Health and Welfare
- Brazil's INPI Approves Patent for Our Single-Chain Immunoglobulin Fusion Protein Technology Platform.
- The sterile vial line-2 of UBIP's expanded factory passed the GMP inspection of the Ministry of Health and Welfare.
- Employee Travel Leave Notice
- Explanation of UBI Pharma's cessation of stock trading on the Taipei Exchange and the current operational status of the company
- UBI Pharma announces its participation in the '2024 TALENT, in Taiwan' alliance for sustainable talent development in Taiwan."
- UBI Pharma's explanation for the termination of stock trading on the Taipei Exchange
- UBI Pharma passes GMP inspection by the UK MHRA.
- UBI Pharma applies to the Taiwan Food and Drug Administration (TFDA) for drug inspection registration of the biosimilar drug erythropoietin UB-851.
- UBI Pharma passes GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
- UBI Pharma obtains a US patent certificate for the "Single-Chain Immunoglobulin Fusion Protein Technology Platform."
- UBI Pharma applies to the TFDA for drug inspection registration of the new compound drug NDF01 for the treatment of HIV infection.
- UBI Pharma signs an investment and exclusive licensing sales agreement with Ory Biotech Co., Ltd. for the bio-similar drug UB-851.
- UBI Pharma's Hsinchu plant receives formal Establishment Inspection Report (EIR) approval from the United States Food and Drug Administration (FDA).
- UBI Pharma's proprietary product, Voriconazole Injection, has received approval for Abbreviated New Drug Application (ANDA) from the United States.
- UBI Pharma Inc. responds to community greening and carbon reduction tree planting activities
- UBI Pharma Inc. Achieves Another Milestone in the US Market: Its Anti-Fungal Injection Generic Product Approved by the US FDA
- UBI Pharma Inc. Expands Southeast Asian Market: Epilepsy Drug Levetiracetam Was Approved in Malaysia
- Bioequivalence Study is Completed for UBIP’s New Formulation New Drug NDF01, and Will Proceed to NDA Filing Soon
- UBI Pharma Inc. passed the TTQS(Talent Quality-management System) assessment and received the bronze medal
- The Clinical Study Report of the Phase III Clinical Trial of UBIP’s Recombinant Human Erythropoietin Biosimilar Drug UB-851 Has Been Completed
- The Production Line of UBI Pharma Inc. for Manufacturing Sterile Injectable Drugs Has Been Approved by the U.S. Food and Drug Administration

Media Coverage
- The UK's MHRA has cleared UBI's COVID-19 vaccine, UB-612, after inspecting its manufacturing facility. UBIP's production base in Taiwan has obtained GMP certification!
- UBIP has completed the submission for its in-house developed biosimilar drug (UB-851, EPO) to TFDA
- UBI Pharma Inc.'s "Single-Chain Immunoglobulin Fusion Protein Technology" has been granted a patent in the USA
- Merdury Biopharmaceutical Corporation Partners with UBI Pharma Inc. to Pioneer Sildenafil Orally Disintegrating Tablets for the $4.5 Billion Global ED Drug Market
- UBI Pharma Inc. as received two prestigious awards at the 20th National Brand Yushan Awards (2023)
- UBI Pharma Inc. has commissioned EirGenix to produce the biosimilar drug UB-851, paving the way for an early international market expansion.
- UBI Pharma Inc. Passes Ukrainian Inspection, Joining Lumosa Therapeutics to Enter European Market
- The Phase III Trial of the EPO Injection Developed by UBI Pharma Inc. has been Completed, the Company Plans to Submit an Application for Drug Licensing to the TFDA
- Successful Unblinding of the Phase III Clinical Trial of Erythropoietin Conducted by UBI Pharma Inc.
- The Unique Long-acting Technology Platform Developed by UBI Pharma Inc. Has Been Granted a Patent by the United States and Canada
- TFDA Approves the Phase I Clinical Trial of the New Drug UB-852 Developed by UBI Pharma Inc.
- TFDA Approves the Phase I Clinical Trial of the New Targeted Anticancer Drug UB-941 Developed by UBI Pharma Inc.

Events

Home
News
Press Release
UBI Pharma’s UB-851, a Biosimilar Short-Acting Recombinant Human Erythropoietin, Demonstrates Strong Clinical Biosimilarity and Earns Publication in an International Medical Journal

UBI Pharma’s UB-851, a Biosimilar Short-Acting Recombinant Human Erythropoietin, Demonstrates Strong Clinical Biosimilarity and Earns Publication in an International Medical Journal

UBI Pharma Inc.

TEL +886-3-5977676
FAX +886-3-5981173
Address No.45, Guangfu N. Rd., Hukou Township, Hsinchu County 303036, Taiwan (R.O.C.)

Adverse Reaction Contact
24 hour phone +886-800-035-511
email pharmacovigilance@ubi-pharma.com

© 2026 UBI Pharma Inc. All rights reserved. Designed By Winho